ExploreWatchlistsPricing
  1. US-listed companies
  2. Adaptimmune Therapeutics PLC
  3. Financials
  4. Common stock and paid-in capital

Adaptimmune Therapeutics PLC (ADAPY)

Market cap
$5.73M
P/E ratio
SummaryFinancials
Period EndCommon stock and paid-in capital (Million USD)YoY (%)
Dec 31, 20241,108+3.87%
Dec 31, 20231,066+7.50%
Dec 31, 2022992+3.24%
Dec 31, 2021961+2.55%
Dec 31, 2020937+59.75%
Dec 31, 2019587+1.99%
Dec 31, 2018575+26.06%
Dec 31, 2017456+33.45%
Dec 31, 2016342

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat